Eli Lilly CEO John Lechleiter talks about the impact of the dollar, taxes, and the problem he sees with the Trans-Pacific Partnership agreement. Also Lechleiter provides an update on Alzheimer's treatment.
Eli Lilly CEO John Lechleiter discusses cycles in the industry and products coming out of the company's labs. We're very optimistic about our future, says Lechleiter. We have a chance to introduce 20 new products in the next ten years and are off to a good running start.
Ringing today's opening bell are Eli Lilly and Company CEO John Lechleiter, at the NYSE, and USO of Metropolitan New York Brian Whiting, at the Nasdaq.
Today's bell ringers are Eli Lilly and Company CEO John Lechleiter, at the NYSE, and USO of Metropolitan New York Brian Whiting, at the Nasdaq.
The FMHR traders and Stephanie Link of TIAA Global Asset Management, take their positions on stocks in earnings news, including Procter & Gamble's turnaround story.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
John Lechleiter, Eli Lilly CEO, breaks down the pharma giant's numbers and discusses new products in the pipeline, and provides an update on its diabetes drug, Humalog.